Skip to main content
. 2015 Oct 21;7(3):3623–3634. doi: 10.18632/oncotarget.6211

Table 2. Patient's distribution by FAB classification and mutation analysis.

N % Total
FAB classification 43
M1 7 16.3
M2 14 32.5
M5 22 51.2
Mutation analysis Analyzed (N, % of total) (37, 86%)
NPM1 3 8.1
FLT3-ITD 2 5.4

FAB, French-American-British; NPM1, nucleophosmin; FLT3-ITD, FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication